Skip to main content

Table 2 Predicted per year benefits of Wolbachia programmes in four sites. Only eligible areas (at least 1000 people per km2) receive treatment. All costs are in 2018 US dollars and are not discounted. Figures in brackets represent 95% uncertainty intervals

From: The cost-effectiveness of controlling dengue in Indonesia using wMel Wolbachia released at scale: a modelling study

 Committed areaScale-up scenario
Yogyakarta CityRemaining Yogyakarta SARJakartaBali
Baseline cases per year (area wide)14,488 (2955–47,858)93,604 (21,527–249,843)444,528 (97,542–1,189,217)117,840 (27,862–324,114)
Post Wolbachia cases per year (area wide)722 (0–30,140)36,674 (6805–180,567)127,712 (0–749,850)62,033 (9810–237,984)
Area-wide percent reduction (%)94.4 (36.5–100)59.1 (25.6–69.6)65.7 (36.7–100)52.4 (24.2–66.9)
Percent reduction within treated areas94.4 (36.5–100)87.2 (37.2–100)65.7 (36.7–100)82.8 (37.3–100)
Averted medical costs per year (millions USD)0.46 (0.14–1.19)2.16 (0.67–4.70)12.91 (4.49–25.08)2.58 (0.82–5.11)
Averted societal costs per year (millions USD)0.52 (0.21–0.98)2.36 (1.05–4.28)14.17 (6.09–24.27)2.77 (1.23–4.74)